AU2001290786A1 - Nitrogen-containing compounds and their use as glycine transport inhibitors - Google Patents
Nitrogen-containing compounds and their use as glycine transport inhibitorsInfo
- Publication number
- AU2001290786A1 AU2001290786A1 AU2001290786A AU9078601A AU2001290786A1 AU 2001290786 A1 AU2001290786 A1 AU 2001290786A1 AU 2001290786 A AU2001290786 A AU 2001290786A AU 9078601 A AU9078601 A AU 9078601A AU 2001290786 A1 AU2001290786 A1 AU 2001290786A1
- Authority
- AU
- Australia
- Prior art keywords
- amino
- alkyl
- group
- ethyl
- trichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23254000P | 2000-09-14 | 2000-09-14 | |
US60232540 | 2000-09-14 | ||
PCT/US2001/028431 WO2002022581A1 (fr) | 2000-09-14 | 2001-09-13 | Composes azotes et leur utilisation comme inhibiteurs de transport de la glycine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001290786A1 true AU2001290786A1 (en) | 2002-03-26 |
Family
ID=22873542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001290786A Abandoned AU2001290786A1 (en) | 2000-09-14 | 2001-09-13 | Nitrogen-containing compounds and their use as glycine transport inhibitors |
Country Status (6)
Country | Link |
---|---|
US (2) | US20020082283A1 (fr) |
EP (1) | EP1324986A1 (fr) |
JP (1) | JP2004518628A (fr) |
AU (1) | AU2001290786A1 (fr) |
CA (1) | CA2422044A1 (fr) |
WO (1) | WO2002022581A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003257589A1 (en) | 2002-08-22 | 2004-03-11 | Sumitomo Pharmaceuticals Company, Limited | Remedy for integration dysfunction syndrome |
US20040152740A1 (en) * | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives for use as glycine transport inhibitors |
US20040152741A1 (en) * | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives and their use as glycine transport inhibitors |
KR20060004967A (ko) * | 2003-04-30 | 2006-01-16 | 하. 룬트벡 아크티에 셀스카브 | 방향족 옥시페닐 및 방향족 설파닐페닐 유도체 |
GB0314479D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
US20060142276A1 (en) | 2003-06-23 | 2006-06-29 | Yukihiro Ohno | Therapeutic agent for senile dementia |
EP2357474A1 (fr) | 2004-02-20 | 2011-08-17 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone pour son utilisation dans le traitement d'un dysfonctionnement de la mémoire et de l'apprentissage par schizophrénie |
WO2005090299A2 (fr) * | 2004-03-12 | 2005-09-29 | Wyeth | Carbamates utilises en tant qu'agents anti-vih |
GB0408772D0 (en) * | 2004-04-20 | 2004-05-26 | Glaxo Group Ltd | Compounds |
WO2006000222A2 (fr) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | Combinaison d'un antipsychotique et d'un inhibiteur de type 1 transporteur de glycine pour le traitement de la schizophrenie |
ATE430142T1 (de) * | 2004-12-09 | 2009-05-15 | Hoffmann La Roche | Phenylpiperazin-methanon-derivate |
WO2006079467A1 (fr) | 2005-01-26 | 2006-08-03 | F. Hofmann-La Roche Ag | Derives methanone phenyliques et leur utilisation en tant qu'inhibiteurs du transporteur 1 de la glycine |
EP1917244A2 (fr) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5 |
CA2661863A1 (fr) * | 2006-08-30 | 2008-03-06 | F. Hoffmann-La Roche Ag | Inhibiteurs de glyt-1 |
JP5546540B2 (ja) * | 2008-08-12 | 2014-07-09 | アラーガン インコーポレイテッド | スフィンゴシン‐1‐リン酸(s1p)レセプター拮抗薬およびその使用方法 |
EP2570403B1 (fr) * | 2010-05-14 | 2015-03-11 | Chinese PLA General Hospital | Composés d'urée et leur utilisation dans l'inhibition de l'apoptose |
EP2573078B1 (fr) | 2010-05-14 | 2016-11-02 | Chinese PLA General Hospital | Composés d'acrylamide et leur utilisation dans l'inhibition de l'apoptose |
CN102241673B (zh) * | 2010-05-14 | 2015-06-24 | 中国人民解放军总医院 | 丙烯酰胺类化合物及其医药用途 |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
EP3085690B1 (fr) | 2013-12-20 | 2019-09-11 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Nouveau composé d'urée, son procédé de production et son application |
US20190388426A1 (en) | 2017-01-30 | 2019-12-26 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
EP3820471A4 (fr) * | 2018-07-10 | 2022-04-13 | Ctec Llc | Traitement de l'encéphalopathie traumatique chronique |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1810293A1 (de) | 1968-11-22 | 1970-06-11 | Bayer Ag | N-Fluoracetylamino-methyl-harnstoffe und Verfahren zu ihrer Herstellung |
US4146646A (en) | 1976-02-12 | 1979-03-27 | Fisons Limited | Bis-amide fungicidal compounds |
JPS55111451A (en) | 1979-02-19 | 1980-08-28 | Nippon Kayaku Co Ltd | Novel 2-hydroxybenzamide derivative and agricultural and horticultural soil bactericide |
ES2270462T3 (es) * | 1996-05-31 | 2007-04-01 | Allelix Neuroscience Inc. | Producto farmaceutico para el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
EP0918767A4 (fr) * | 1996-05-31 | 2000-04-26 | Allelix Neuroscience Inc | Produit pharmaceutique pour le traitement de troubles neurologiques et neuropsychiatriques |
AU2030999A (en) | 1998-01-09 | 1999-07-26 | Allelix Neuroscience, Inc. | Glycine transport inhibitors |
WO1999044596A2 (fr) * | 1998-03-06 | 1999-09-10 | Janssen Pharmaceutica N.V. | Inhibiteurs du transport de la glycine |
EP1058684A1 (fr) * | 1998-03-06 | 2000-12-13 | Janssen Pharmaceutica N.V. | Inhibiteurs du transport de la glycine |
DE60036476T2 (de) | 1999-08-03 | 2008-06-12 | Abbott Laboratories, Abbott Park | Kalium kanalaktivatoren |
-
2001
- 2001-09-13 AU AU2001290786A patent/AU2001290786A1/en not_active Abandoned
- 2001-09-13 CA CA002422044A patent/CA2422044A1/fr not_active Abandoned
- 2001-09-13 JP JP2002526834A patent/JP2004518628A/ja not_active Withdrawn
- 2001-09-13 US US09/951,170 patent/US20020082283A1/en not_active Abandoned
- 2001-09-13 EP EP01970824A patent/EP1324986A1/fr not_active Withdrawn
- 2001-09-13 US US10/344,962 patent/US6946474B2/en not_active Expired - Fee Related
- 2001-09-13 WO PCT/US2001/028431 patent/WO2002022581A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2004518628A (ja) | 2004-06-24 |
US6946474B2 (en) | 2005-09-20 |
WO2002022581A1 (fr) | 2002-03-21 |
US20040034069A1 (en) | 2004-02-19 |
US20020082283A1 (en) | 2002-06-27 |
EP1324986A1 (fr) | 2003-07-09 |
CA2422044A1 (fr) | 2002-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6946474B2 (en) | Nitrogen-containing compounds and their use as glycine transport inhibitors | |
US6794405B2 (en) | Alicyclic imidazoles as H3 agents | |
CA2185019C (fr) | Isoxazolines, inhibiteurs de la liberation du fnt | |
AU2006209207C1 (en) | 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | |
CN101506216A (zh) | 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物 | |
FR2540495A1 (fr) | Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus | |
CZ304702B6 (cs) | (4R) a (4S) diastereoizomery (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamidu, farmaceutická kompozice s jejich obsahem a jejich použití | |
CA2152184A1 (fr) | Derives de thiazolidine, leur preparation et les medicaments les contenant | |
EA010852B1 (ru) | Пиперидиновые соединения и фармацевтические композиции, их содержащие | |
NO321606B1 (no) | Pyrrolderivater og medisinsk sammensetning | |
WO2010013242A1 (fr) | Sels de carboxylate de pyridoxine-lactame substitués | |
JP2001500107A (ja) | 神経障害および神経心理学的障害の治療のための製剤学的薬剤 | |
CA2126687A1 (fr) | Derives de substitution peptidyliques renfermant de l'acide phosphonique, agents antidegeneratifs | |
KR100468253B1 (ko) | 씨엔에스 질환에 대한 카보닐아미노 유도체의 용도 | |
HUT61574A (en) | Process for producing ureq derivatives and pharmaceutical compositions comprising same | |
US7049343B2 (en) | Substituted hydrazine derivatives | |
WO2023014927A1 (fr) | Promédicaments de tapinarof | |
JP2003534308A (ja) | 新規mmp−2/mmp−9阻害剤 | |
WO2022056068A1 (fr) | Inhibiteurs à petites molécules d'enpp1 | |
US20050171195A1 (en) | P2X7 antagonists for treating neuropathic pain | |
RU2114828C1 (ru) | Энантиомеры ароматических азотсодержащих производных и их соли с неорганическими или органическими кислотами и способ их получения | |
WO2017127417A1 (fr) | Composés phosphopantothénate | |
JPH01279834A (ja) | 4―(3―ホスホノ―2―プロペニル)―2―ピペラジンカルボン酸の新規用途 | |
AU2012250280A1 (en) | 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity |